FCB lands two DTC accounts

FCB was awarded the DTC advertising for Hoffman-LaRoche's two drugs, Pegasys and Copegus, that treat hepatitis C. Annual media spending for upcoming campaigns could exceed $30 million, sources said.
The agency, which is a unit of the Interpublic Group, pitched against three other undisclosed agencies.
Pegasys and Copegus were approved by the FDA two years ago, but this marks the first DTC campaign for both. The FDA has granted a six-month Priority Review Status to the supplemental new biologics license application (sBLA) for the combination therapy of Pegasys in combination with Copegus for the treatment of hepatitis C in patients who are also infected with HIV. Roche submitted this file with the FDA in August 2004.
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.